Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.
The Pruritus- Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.
Key Targets in the Pruritus Pipeline Drugs Market
The key targets in the Pruritus pipeline drugs market are Kappa Type Opioid Receptor, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sphingosine 1-Phosphate Receptor 1, Substance P Receptor, Tyrosine Protein Kinase JAK1, Voltage Dependent T Type Calcium Channel, and Voltage Dependent T Type Calcium Channel Subunit Alpha 1G among others.
Pruritus Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Pruritus Pipeline Drugs Market
The key mechanisms of action in the Pruritus pipeline drugs market are Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Ileal Sodium/Bile Acid Cotransporter Inhibitor, Mas Related G Protein Coupled Receptor Member X2 Antagonist, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and 5-Hydroxytryptamine Receptor 2A Antagonist.
Pruritus Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Pruritus Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Pruritus pipeline drugs market are Oral, Subcutaneous, Intravenous, Topical, Inhalational, Buccal, Nasal, and Rectal.
PruritusPipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Pruritus Pipeline Drugs Market
The key molecule types in the Pruritus pipeline drugs market are Monoclonal Antibody, Small Molecule, Synthetic Peptide, Peptide and Biologic among others.
Pruritus Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Pruritus Pipeline Drugs Market
The major companies in the Pruritus pipeline drugs market are Cara Therapeutics Inc, Amgen Inc, Asana BioSciences LLC, Avior Bio Inc, Toray Industries Inc, Trevi Therapeutics Inc, 9 Meters Biopharma Inc, AfaSci Inc, Akaal Pharma Pty Ltd, and Albireo Pharma Inc among others.
Pruritus Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Pruritus Pipeline Drugs Market Overview
| Key Targets | Kappa Type Opioid Receptor, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sphingosine 1-Phosphate Receptor 1, Substance P Receptor, Tyrosine Protein Kinase JAK1, Voltage Dependent T Type Calcium Channel, and Voltage Dependent T Type Calcium Channel Subunit Alpha 1G |
| Key Mechanisms of action | Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Ileal Sodium/Bile Acid Cotransporter Inhibitor, Mas Related G Protein Coupled Receptor Member X2 Antagonist, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and 5-Hydroxytryptamine Receptor 2A Antagonist |
| Key Routes of Administration | Oral, Subcutaneous, Intravenous, Topical, Inhalational, Buccal, Nasal, and Rectal |
| Key molecule types | Monoclonal Antibody, Small Molecule, Synthetic Peptide, Peptide and Biologic |
| Major companies | Cara Therapeutics Inc, Amgen Inc, Asana BioSciences LLC, Avior Bio Inc, Toray Industries Inc, Trevi Therapeutics Inc, 9 Meters Biopharma Inc, AfaSci Inc, Akaal Pharma Pty Ltd, and Albireo Pharma Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus
- The pipeline guide reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pruritus therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pruritus therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Pruritus
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pruritus
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AfaSci Inc
Akaal Pharma Pty Ltd
Albireo Pharma Inc
Amgen Inc
AntalGenics SL
AOBiome LLC
Asana BioSciences LLC
Avior Bio Inc
BioArdis LLC
Biomimetix JV LLC
Cara Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Clexio Biosciences Ltd
DermaXon LLC
DongKoo Bio & Pharma Co Ltd
ELORAC Inc
Escient Pharmaceuticals Inc
Evommune Inc
Genu Pharma Co Ltd
GlaxoSmithKline Plc
Jiangsu Hengrui Medicine Co Ltd
Kiniksa Pharmaceuticals Ltd
Kissei Pharmaceutical Co Ltd
Lumosa Therapeutics Co Ltd
MC2 Therapeutics AS
Mirum Pharmaceuticals Inc
Neurim Pharmaceuticals Ltd
Patagonia Pharmaceuticals LLC
Peptide Logic LLC
Pfizer Inc
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
Saniona AB
Sanwa Kagaku Kenkyusho Co Ltd
Shanton Pharma Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sienna Biopharmaceuticals Inc
Sunny Pharmtech Inc
Suzhou Connect Biopharmaceuticals Ltd
Teikoku Pharma USA Inc
Tioga Pharmaceuticals Inc
Titan Pharmaceuticals Inc
Toray Industries Inc
Trevi Therapeutics Inc
Vivozon Inc
YIRUI Pharmaceutical Technology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Pruritus pipeline drugs market?
The key targets in the Pruritus pipeline drugs market are Kappa Type Opioid Receptor, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sphingosine 1-Phosphate Receptor 1, Substance P Receptor, Tyrosine Protein Kinase JAK1, Voltage Dependent T Type Calcium Channel, and Voltage Dependent T Type Calcium Channel Subunit Alpha 1G .
-
What are the key mechanisms of action in the Pruritus pipeline drugs market?
The key mechanisms of action in the Pruritus pipeline drugs market are Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Ileal Sodium/Bile Acid Cotransporter Inhibitor, Mas Related G Protein Coupled Receptor Member X2 Antagonist, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and 5-Hydroxytryptamine Receptor 2A Antagonist.
-
What are the key routes of administration in the Pruritus pipeline drugs market?
The key routes of administration in the Pruritus pipeline drugs market are Oral, Subcutaneous, Intravenous, Topical, Inhalational, Buccal, Nasal, and Rectal.
-
What are the key molecule types in the Pruritus pipeline drugs market?
The key molecule types in the Pruritus pipeline drugs market are Monoclonal Antibody, Small Molecule, Synthetic Peptide, Peptide and Biologic.
-
What are the major companies in the Pruritus pipeline drugs market?
The major companies in the Pruritus pipeline drugs market are Cara Therapeutics Inc, Amgen Inc, Asana BioSciences LLC, Avior Bio Inc, Toray Industries Inc, Trevi Therapeutics Inc, 9 Meters Biopharma Inc, AfaSci Inc, Akaal Pharma Pty Ltd, and Albireo Pharma Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Dermatology reports